Beam Therapeutics Inc.
NASDAQ:BEAMBiotechnology
+$0.48 today
- Market cap
- $2.17B
- Beta
- 2.20
- P/E (TTM)
- -52.3
- EPS (TTM)
- -$0.63
Volume 4.86M
Average 2.11M
BEAM Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Beam Therapeutics Inc.NASDAQ: BEAM
Operating Margin · Q2 FY2026 · quarter ended Jun 2026
Operating margin narrows to -25827.1%
Operating margin was -25827.1% in Q2 FY2026, down 24407.9 pp from a year earlier. On a trailing-twelve-month basis it was -242.3%, up 497.7 pp year over year. Over 3 fiscal years it widened by 281.0 pp.
Context
- Operating margin widened in 2 of the last 3 fiscal years.
What to watch
Whether operating margin reaches the consensus estimate from 10 analysts of -1135.2% for the fiscal year ending Dec 2026, down from -274.6% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -25827.1%-25489.3 pp QoQ
- Last fiscal yearDec 2025
- -274.6%+379.7 pp YoY
- LTMJun 2026
- -242.3%+497.7 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -274.6%
- Year-over-year change
- +379.7pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -274.6% | +379.7pp |
| FY2024 | 2024-12-31 | -654.3% | -607.5pp |
| FY2023 | 2023-12-31 | -46.7% | +508.9pp |
| FY2022 | 2022-12-31 | -555.6% | +201.4pp |
| FY2021 | 2021-12-31 | -757.0% | — |
Operating Margin vs competitors
How BEAM compares with its peers on the latest reported figures
- BEAM's LTM Jun 2026 operating margin of -242.3% is the 3rd highest of the 8 companies compared; the peer median is -636.6%.
- Its year-over-year change of +497.7 pp is the 2nd highest of 8, against a peer median of +43.4 pp.
- Over three fiscal years its change of +281.0 pp compares with a peer median of +227.4 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -67.6% | +43.4 pp | +422.4 pp | |
| LTM Mar 2026 | -86.8% | -0.6 pp | +96.1 pp | |
| LTM Jun 2026 | -242.3% | +497.7 pp | +281.0 pp | |
| LTM Mar 2026 | -297.5% | +428.9 pp | +901.1 pp | |
| LTM Mar 2026 | -636.6% | +550.8 pp | +227.4 pp | |
| LTM Mar 2026 | -1175.7% | +473.1 pp | -452.3 pp | |
| LTM Sep 2026 | -2104.9% | -834.8 pp | +138203.3 pp | |
| LTM Mar 2026 | -2207.5% | -704.0 pp | -1902.2 pp | |
| FY2025 | — | — | — | |
| Peer median (excluding BEAM) | -636.6% | +43.4 pp | +227.4 pp | |
Competitors are the stored peer set for BEAM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 51.84M | 60.92M | 377.71M | 63.52M | 139.74M |
| Cost of Revenue | 232.13M | 311.59M | 0 | 367.56M | 22.29M |
| Gross Profit | (180.29M) | (250.67M) | 377.71M | (304.04M) | 117.45M |
| Gross Margin | -347.8% | -411.5% | 100.0% | -478.7% | 84.0% |
| Research & Development | 387.09M | 311.59M | 437.38M | 367.56M | 409.62M |
| Selling, General & Admin | 57.22M | 87.81M | 116.81M | 111.53M | 113.82M |
| Operating Expenses | 212.18M | 87.81M | 554.19M | 111.53M | 501.14M |
| Depreciation & Amortization | 7.45M | 14.15M | 20.01M | 21.93M | 22.29M |
| EBITDA | (230.06M) | (271.53M) | (111.15M) | (354.78M) | (13.97M) |
| EBITDA Margin | -443.8% | -445.7% | -29.4% | -558.5% | -10.0% |
| Operating Income | (392.47M) | (338.48M) | (176.49M) | (415.57M) | (383.69M) |
| Operating Margin | -757.0% | -555.6% | -46.7% | -654.3% | -274.6% |
| Interest Income | 0 | 15.3M | 46.68M | 49.09M | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 43.73M |
| Other Income / Expenses | 21.83M | 52.8M | 45.32M | 38.87M | 303.7M |
| Income Before Tax | (370.64M) | (285.68M) | (131.16M) | (376.7M) | (79.99M) |
| Pre-Tax Margin | -714.9% | -468.9% | -34.7% | -593.1% | -57.2% |
| Income Tax Expense | 0 | 3.41M | 1.37M | 39K | 0 |
| Net Income | (370.64M) | (289.09M) | (132.53M) | (376.74M) | (79.99M) |
| Net Margin | -714.9% | -474.5% | -35.1% | -593.1% | -57.2% |
| EPS (Basic) | (5.77) | (4.13) | (1.72) | (4.58) | (0.81) |
| EPS (Diluted) | (5.77) | (4.13) | (1.72) | (4.58) | (0.81) |
| Weighted Avg Shares | 64.23M | 70.02M | 77.15M | 82.31M | 98.91M |
| Weighted Avg Shares (Diluted) | 64.23M | 70.02M | 77.15M | 82.31M | 98.91M |
Beam Therapeutics Inc.
NASDAQ:BEAM
Intrinsic Alpha fair value
Locked
Current Price
$21.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.